Literature DB >> 15140915

Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells.

Andrew B Maksymowych1, Lance L Simpson.   

Abstract

Experiments were done to help localize the minimum essential domain within the botulinum toxin molecule that is necessary for binding and transport across human gut epithelial cells. The data demonstrated that the neurotoxin alone, in the absence of auxiliary proteins, undergoes transcytosis. The neurotoxin by itself was examined in the single chain (unnicked serotype B) and dichain (nicked serotype B, nicked serotype A) forms, and all displayed the ability to bind and penetrate epithelial barriers. In addition, the single chain and dichain molecules were examined in the oxidized and reduced states, and again all forms were transported. To further define the minimum essential domain, experiments were done with two toxin fragments: 1) the heavy chain, which was derived from native toxin, and 2) the carboxy-terminal portion of the heavy chain, which was generated by recombinant techniques. Interestingly, both fragments were fully competent in crossing epithelial barriers. These data suggest that a polypeptide derived from the toxin could be used as a carrier domain to transport other molecules across epithelial cells. In related experiments, physiological (i.e., potassium depletion) and pharmacological (i.e., chlorpromazine) manipulations were used to implicate clathrin-coated pits/vesicles as the structures responsible for endocytosis of toxin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140915     DOI: 10.1124/jpet.104.066845

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route.

Authors:  Fetweh H Al-Saleem; Denise M Ancharski; Suresh G Joshi; M Elias; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

Review 3.  Bacterial Signaling to the Nervous System through Toxins and Metabolites.

Authors:  Nicole J Yang; Isaac M Chiu
Journal:  J Mol Biol       Date:  2017-01-06       Impact factor: 5.469

4.  Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.

Authors:  David M White; Sabine Pellett; Mark A Jensen; William H Tepp; Eric A Johnson; Barry G W Arnason
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

5.  Role of neurotoxin associated proteins in the low pH induced structural changes in the botulinum neurotoxin complex.

Authors:  Gowri Chellappan; Raj Kumar; Shuowei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2014-12       Impact factor: 2.371

6.  Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route.

Authors:  Easwaran Ravichandran; Fetweh H Al-Saleem; Denise M Ancharski; Mohammad D Elias; Ajay K Singh; Mohammad Shamim; Yujing Gong; Lance L Simpson
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

7.  Comparison of oral toxicological properties of botulinum neurotoxin serotypes A and B.

Authors:  Luisa W Cheng; Thomas D Henderson
Journal:  Toxicon       Date:  2011-05-11       Impact factor: 3.033

8.  Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare.

Authors:  Fetweh H Al-Saleem; Zidoon Nasser; Rebecca M Olson; Linsen Cao; Lance L Simpson
Journal:  J Pharmacol Exp Ther       Date:  2011-05-17       Impact factor: 4.030

Review 9.  Interaction of botulinum toxin with the epithelial barrier.

Authors:  Yukako Fujinaga
Journal:  J Biomed Biotechnol       Date:  2010-02-14

10.  Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.

Authors:  Tsuyoshi Takahashi; Suresh G Joshi; Fetweh Al-Saleem; Denise Ancharski; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.